Back to discover
Drug

Semaxanib

Late-stage clinical development
ClassVascular endothelial growth factor receptor inhibitor
RxNorm337552ChEMBLCHEMBL276711UNII71IA9S35AJ
4
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase I Study of SU5416 in Combination With Gemcitabine/Cisplatin in Patients With Advanced Solid Tumors

Clinical trial2013-12-19Status unknown · ClinicalTrials.gov

A Phase III, Randomized, Open-Label Multicenter, International Study Comparing The Combination Of SU5416/Irinotecan/5-Fluorouracil/Leucovorin Versus Irinotecan/Fluorouracil/Leucovorin Alone As First-Line Therapy Of Patient With Previously Untreated Metastatic Colorectal Cancer

Clinical trial2013-12-19Status unknown · ClinicalTrials.gov

A Phase II Trial of SU5416 (NSC #696819) in Previously Treated Patients With Advanced, Metastatic and/or Locally Recurrent Soft Tissue Sarcomas

Clinical trial2013-02-11Completed · ClinicalTrials.gov

A Phase II, Pharmacologic and Biologic Study of Escalating Doses of Thalidomide (NSC #66847) Administered Orally Once a Day in Combination With a Fixed Dose of SU5416 (NSC #696819) in Patients With Metastatic Melanoma

Clinical trial2013-02-11Completed · ClinicalTrials.gov

A Phase II Trial of SU5416 (NSC #696819) in Patients With Metastatic Melanoma

Clinical trial2013-01-24Terminated · ClinicalTrials.gov

A Phase I/II Study of Escalating Doses of SU5416 (NSC 696819) in Combination With CPT-11 in Patients With Advanced Colorectal Carcinoma

Clinical trial2013-01-23Completed · ClinicalTrials.gov

Phase II Study of SU5416 (NSC 696819) for Patients With Progressive Metastatic Renal Cancer Failing Prior Biologic Therapy or 5-Fluorouracil Containing Regimens

Clinical trial2013-01-23Terminated · ClinicalTrials.gov

Phase II Trial of Liposomal Daunorubicin (Daunoxome) and SU5416 (NSC 696819) in Patients With AML, RAEB, RAEB-T or CMML in Transformation Refractory to One Course of Induction Chemotherapy

Clinical trial2013-01-23Completed · ClinicalTrials.gov

A Multicenter, Dose Escalating Study in Patients With Cutaneous AIDS-Related Kaposi's Sarcoma

Clinical trial2012-08-23Completed · ClinicalTrials.gov

Phase I Trial of SU5416 in Combination With Weekly Paclitaxel in Patients With Advanced Malignancies

Clinical trial2010-01-13Completed · ClinicalTrials.gov

A Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

Clinical trial2009-12-04Completed · ClinicalTrials.gov

Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced Colorectal Cancer

Clinical trial2009-08-01Terminated · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Semaxanib
RxNorm CUI
337552
ChEMBL ID
CHEMBL276711
UNII
71IA9S35AJ
Primary mechanism
Vascular endothelial growth factor receptor inhibitor

Pharmacology & targets

4 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Vascular endothelial growth factor receptor 1
FLT1 · P17948
INHIBITORVascular endothelial growth factor receptor inhibitor
Vascular endothelial growth factor receptor 3
FLT4 · P35916
INHIBITORVascular endothelial growth factor receptor inhibitor
Vascular endothelial growth factor receptor 2
KDR · P35968
INHIBITORVascular endothelial growth factor receptor inhibitor
Mast/stem cell growth factor receptor Kit
KIT · P10721
INHIBITORStem cell growth factor receptor inhibitor

Clinical trials

27 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
27
registered trials across all phases
LATEST COMPLETION 2009
2
Late-stage (III+)
21
Completed
6
Discontinued
PHASE DISTRIBUTIONn = 27
Phase 18Phase 1 / 25Phase 212Phase 32

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase II Trial of SU5416 (NSC# 696819) in Patients With Malignant Mesothelioma

CompletedPH IINational Cancer Institute (NCI)n=452009

A Randomized, Open-Label, Multicenter Phase III Study of 5-FU/Leucovorin With or Without Concomitant SU5416 in Patients With Metastatic Colorectal Cancer

CompletedPH IIIPfizer2007

Phase II Trial of SU5416 and Interferon Alfa 2B in Unresectable or Metastatic Renal Cell Carcinoma

CompletedPH IICity of Hope Medical Center2007

A Phase II Trial of SU5416 (NSC# 686819) in Patients With Hormone Refractory Prostate Cancer

CompletedPH IIUniversity of Chicagon=362006

A Phase I Pharmacodynamic Trial of SU5416 (NSC 696819)

CompletedPH ICase Comprehensive Cancer Centern=192005

A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas

CompletedPH I/IISidney Kimmel Comprehensive Cancer Center at Johns Hopkins2005
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials